Posted by Michael Wonder on 01 Dec 2023
Pembrolizumab with trastuzumab and chemotherapy for the first-line treatment of patients with advanced HER2 positive gastric or gastro-oesophageal junction cancer
1 December 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of pembrolizumab in combination with trastuzumab and chemotherapy in the NHS in England.
For the time being, the combination of pembrolizumab and trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy is not recommended for the first-line treatment of adults with locally advanced, unresectable or metastatic HER2 positive gastric or gastro-oesophageal junction adenocarcinoma whose tumours express PD-L1 with a combined positive score of 1 or more.
